Shield Therapeutics PLC operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shield Therapeutics PLC with three other
companies in this sector in the United Kingdom:
Tissue Regenix Group PLC
sales of £11.62 million [US$15.01 million]
of which 55%
(£12.53 million [US$16.18 million]
of which 100%
was Medical Service), and
(£11.48 million [US$14.84 million]
of which 76%
was Research and development).